GILDGilead SciencesRunning, no new patients
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Endometrial Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 640 (planned)
- Started
- Aug 28, 2024
- Main results expected
- Jun 2029
- Fully finished
- Jun 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 27 months
Overall Survival (OS)
Measured over: Up to approximately 47 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06486441 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC